Academic Journal
Q1European Journal of Heart Failure
About European Journal of Heart Failure
European Journal of Heart Failure is a scholarly journal published by John Wiley and Sons Ltd. SCImago 2025 places it in Q1 with an SJR of 4.965 and an H-index of 195.
Its listed coverage is 1999-2025 and its research categories include Cardiology and Cardiovascular Medicine (Q1). The 2025 dataset reports 445 documents and 7210 citations across the latest three-year reporting window.
About the European Journal of Heart Failure
The European Journal of Heart Failure (EJHF) is a leading peer-reviewed medical journal dedicated to advancing research and clinical practice in the field of heart failure. Published by the prestigious European Society of Cardiology (ESC) on behalf of the Heart Failure Association (HFA), the journal serves as a critical resource for cardiologists, researchers, and healthcare professionals worldwide.
As one of the most cited journals in cardiovascular medicine, the European Journal of Heart Failure focuses on publishing high-quality original research, review articles, clinical trials, case reports, and editorials that address the pathophysiology, diagnosis, treatment, and prevention of heart failure. With a strong emphasis on translational science and clinical relevance, the journal plays a pivotal role in shaping modern cardiovascular medicine and improving patient care.
High-Impact Content and Global Reach
With a high impact factor and international readership, the EJHF is recognized for its rigorous peer-review process and commitment to publishing scientifically sound and clinically impactful content. It provides a global platform for cutting-edge research and expert opinion, making it an essential reference for professionals involved in heart failure care and research.
Topics commonly featured include:
-
Acute and chronic heart failure
-
Heart failure with preserved ejection fraction (HFpEF)
-
Cardiomyopathies
-
Cardiac imaging and biomarkers
-
Advanced heart failure therapies
-
Device therapy and transplantation
-
Heart failure comorbidities and patient management
The journal also plays a key role in disseminating the official guidelines and consensus statements from the Heart Failure Association of the ESC, ensuring that clinicians are equipped with the latest evidence-based practices.
Digital Accessibility and Indexing
The European Journal of Heart Failure is published monthly and is available both in print and online. It is indexed in major databases including PubMed, MEDLINE, Scopus, and Web of Science, which ensures wide visibility and accessibility to the scientific community.
For researchers and clinicians, the journal provides an invaluable source of the most recent developments in heart failure research, from early-phase mechanistic studies to large-scale clinical trials and meta-analyses.
Why Choose the European Journal of Heart Failure?
-
Reputation & Credibility: Backed by the ESC and HFA, the journal is trusted by experts around the world.
-
High-Quality Peer Review: Ensures scientific rigor and clinical relevance.
-
Global Audience: Reach a broad readership of healthcare professionals, academics, and industry experts.
-
Timely Updates: Stay informed with the latest research, guidelines, and innovations in heart failure care.
Submit Your Research
Researchers and clinicians are encouraged to submit their original studies and review articles to the European Journal of Heart Failure. With a fast and efficient review process, authors benefit from the journal’s high visibility and strong reputation in the cardiovascular field.
For more information, visit the official journal page at the ESC website or explore the latest issues online to stay current with breakthroughs in heart failure science.
Journal Metrics
Metrics can change by reporting year. Verify time-sensitive values with the publisher or indexing service.
Aims & Scope
Scope of the European Journal of Heart Failure (EJHF)
The European Journal of Heart Failure (EJHF) is a premier peer-reviewed medical journal that serves as a vital platform for advancing knowledge, research, and clinical practice in the field of heart failure. As the official journal of the Heart Failure Association of the European Society of Cardiology (ESC), the EJHF is dedicated to publishing high-quality articles that significantly contribute to the understanding, diagnosis, treatment, and prevention of heart failure globally.
Focus Areas of the European Journal of Heart Failure
The scope of the European Journal of Heart Failure encompasses a broad spectrum of topics related to heart failure research and patient care. This includes, but is not limited to:
-
Pathophysiology of Heart Failure: The journal features studies exploring the mechanisms behind heart failure, including myocardial remodeling, neurohormonal activation, and cellular and molecular biology.
-
Clinical Research: EJHF publishes original clinical investigations, randomized controlled trials, and real-world evidence studies that influence contemporary clinical guidelines.
-
Pharmacological and Non-pharmacological Treatments: Articles include the latest developments in drug therapies, device-based treatments, surgical interventions, and lifestyle modifications for managing heart failure.
-
Advanced Heart Failure and Transplantation: The journal covers research on mechanical circulatory support, cardiac transplantation, and end-stage heart failure management.
-
Imaging and Diagnostics: Contributions on advancements in echocardiography, cardiac MRI, biomarkers, and diagnostic tools are frequently featured.
-
Heart Failure with Preserved Ejection Fraction (HFpEF) and Reduced Ejection Fraction (HFrEF): Differentiation and tailored management strategies for these major heart failure subtypes are core topics of interest.
Target Audience and Global Reach
The EJHF is intended for cardiologists, heart failure specialists, internists, researchers, and healthcare professionals involved in cardiovascular medicine. The journal enjoys a wide international readership and a high impact factor, making it a trusted source of the latest advancements in heart failure care.
Importance in Clinical Practice and Research
The European Journal of Heart Failure is pivotal in bridging the gap between scientific discovery and clinical application. By publishing editorials, reviews, case reports, and clinical trial data, the EJHF helps healthcare providers stay current with evidence-based practices and innovations in heart failure management.
Commitment to Excellence and Innovation
Maintaining rigorous peer-review standards and editorial integrity, the EJHF ensures that every publication is scientifically robust and clinically relevant. The journal actively encourages interdisciplinary submissions that integrate cardiology with fields such as nephrology, endocrinology, and geriatrics, reflecting the complex, multisystem nature of heart failure.
Recent Research Articles
Latest publications matched automatically by ISSN.
Target-dose vs below-target-dose lisinopril and fosinopril in HFrEF with advanced CKD
Amiya A Ahmed, Frederick Lu, Hans J Moore, Tariq Ahmad et al.
2026-09-09 · DOI: 10.1093/ejhf/xuag257Efficacy of Vericiguat by Background Guideline-Directed Medical Therapy in the VICTOR Trial
Justin A Ezekowitz, Javed Butler, Derek Cyr, Kevin J Anstrom et al.
2026-09-08 · DOI: 10.1093/ejhf/xuag294Pharmacological optimisation in the treatment of Heart Failure in Women (PopS-HF): rationale and design of a prospective pragmatic, multicentre, randomised trial
Andrea Attanasio, Giandomenico Disabato, Gianluigi Guida, Federico Ambrogi et al.
2026-09-08 · DOI: 10.1093/ejhf/xuag293Reply to: Comment on “Artificial Intelligence Fully Automated Analysis of Handheld Echocardiography in Real-World Patients with Suspected Heart Failure”
Ross T Campbell, Kieran F Docherty, Carolyn S P Lam, David J Lowe et al.
2026-09-08 · DOI: 10.1093/ejhf/xuag287Pulmonary disease: the missing dimension in cardiovascular-kidney-metabolic syndrome
Carolyn S P Lam, Tobin Joseph, Mohit Bhutani, Jingmin Zhou et al.
2026-09-07 · DOI: 10.1093/ejhf/xuag291Interpreting potential benefit on secondary outcomes when a trial fails to meet its primary endpoint
Yogesh N V Reddy, Javed Butler, Jan G P Tijssen, Faiez Zannad et al.
2026-09-07 · DOI: 10.1093/ejhf/xuag289Hierarchical composite endpoints in heart failure trials: clarity or confusion?
Ayobami Omodara, Birgit Aßmus, Klaus K Witte, Sam Straw et al.
2026-09-07 · DOI: 10.1093/ejhf/xuag263RSV vaccine for preventing respiratory and cardiovascular hospitalizations in heart failure: a prespecified analysis of the extended DAN-RSV trial
Kristoffer Grundtvig Skaarup, Mats C H Lassen, Marat Yafasov, Manan Pareek et al.
2026-09-07 · DOI: 10.1093/ejhf/xuag282Not All Left Bundle Branch Block Is Created Equal: The Role of Genotype in Dilated Cardiomyopathy
Thomas Fink, Vanessa Sciacca, Philipp Sommer
2026-09-04 · DOI: 10.1093/ejhf/xuag288Renin-independent aldosterone production in heart failure with reduced ejection fraction: A post hoc analysis of the ALOFT trial
Misato Chimura, Kieran F Docherty, Aldo Pietro Maggioni, Roberto Latini et al.
2026-09-03 · DOI: 10.1093/ejhf/xuag290Estimating the prevalence of transthyretin cardiac amyloidosis in the general population
Alberto Aimo, Vincenzo Castiglione, Giuseppe Vergaro, Michele Emdin et al.
2026-09-03 · DOI: 10.1093/ejhf/xuag286Early and Late TAVI Outcomes in Aortic Stenosis with Transthyretin Cardiac Amyloidosis: A Systematic Review
Martina Giusti, Pietro Giorgio Malvindi, Martina Benedetti, Fabio Vagnarelli et al.
2026-09-03 · DOI: 10.1093/ejhf/xuag285Type 2 diabetes and chronic kidney disease combinations in heart failure across the ejection fraction spectrum: clinical associations, medication use, and cause-specific outcomes: a contemporary, real-world analysis of the Swedish Heart Failure Registry
Giulia Ferrannini, Tymon Pol, Charlotta Ljungman, Ulf Dahlström et al.
2026-09-02 · DOI: 10.1093/ejhf/xuag249Contemporary decongestion strategies in acute heart failure: an individual patient data analysis of three randomized controlled trials
Lara E E C Zonneveld, Pieter Martens, Juan C Trullàs, Kevin Damman et al.
2026-09-02 · DOI: 10.1093/ejhf/xuag253Gut microbiome-derived metabolites as prognostic biomarkers in heart failure: a systematic review and meta-analysis
David Koeckerling, Rohin K Reddy, Salmina J Guivala, Timothy Woodhead et al.
2026-09-01 · DOI: 10.1093/ejhf/xuag283Dense but slow: bone remodelling in iron deficiency and heart failure
Sam Majoor, Peter van der Meer, Niels Grote Beverborg
2026-08-31 · DOI: 10.1093/ejhf/xuag235Beyond procedural success after TAVI: is multi-pillar heart failure therapy the next frontier?
Thorald Stolte, Thomas Nestelberger, Felix Mahfoud
2026-08-31 · DOI: 10.1093/ejhf/xuag188Correction to: Ziltivekimab in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the ATHENA and HERMES trials
2026-08-31 · DOI: 10.1093/ejhf/xuag248Diurnal variation in left atrial pressure in ambulatory patients with chronic heart failure
Yuval Amir, Aviv Shaul, Oran Koren, Lior Merav et al.
2026-08-31 · DOI: 10.1093/ejhf/xuag280Blood pressure control and outcomes in heart failure patients with preserved ejection fraction: an individual participant data meta-analysis of four major trials
Sverre E Kjeldsen, Kristian Wachtell, Richard B Devereux
2026-08-30 · DOI: 10.1093/ejhf/xuag269Reviews
Community Reviews
Version History
April 20, 2025 at 5:43 am
April 20, 2025